Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology

MT Newswires Live

2025/12/23

Ginkgo Bioworks (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.

The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.

The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.

Ginkgo plans to support the program with its cell and enzyme engineering capabilities.

Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.

Ginkgo shares rose 8% in recent Monday trading.

Price: 8.75, Change: +0.65, Percent Change: +7.96

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2593437717"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593437717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593437717?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 03:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593437717","market":"sg","top_or_hot":-1,"title":"Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.</p><p>The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.</p><p>The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.</p><p>Ginkgo plans to support the program with its cell and enzyme engineering capabilities.</p><p>Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.</p><p>Ginkgo shares rose 8% in recent Monday trading.</p><p>Price: 8.75, Change: +0.65, Percent Change: +7.96</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-23 03:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks</a> (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.</p><p>The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.</p><p>The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.</p><p>Ginkgo plans to support the program with its cell and enzyme engineering capabilities.</p><p>Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.</p><p>Ginkgo shares rose 8% in recent Monday trading.</p><p>Price: 8.75, Change: +0.65, Percent Change: +7.96</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特種化學制品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593437717","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593437717","pubTimestamp":1766433229,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ginkgo Bioworks  is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.Ginkgo plans to support the program with its cell and enzyme engineering capabilities.Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.Ginkgo shares rose 8%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4109":"特种化学制品","HBCP":"Home Bancorp Inc","DNA":"Ginkgo Bioworks Holdings Inc.","BK4211":"区域性银行","BK7078":"赌场与赌博","BK4139":"生物科技","BK4121":"生命科学工具和服务","DNA.AU":"DONACO INTL LTD","BK4195":"互助储蓄与抵押信贷金融服务"},"translate_title":"Ginkgo Bioworks与卡内基梅隆大学合作开发家庭癌症检测技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA.AU":1,"DNA":1,"HBCP":1.5},"content_text":"Ginkgo Bioworks (DNA) is collaborating with Carnegie Mellon University on an initiative to develop new at-home cancer diagnostics.The Advanced Research Projects Agency for Health awarded funding for the partnership's Platform Optimizing SynBio for Early Intervention and Detection in Oncology, or Poseidon project, which will be led by Carnegie Mellon's Rebecca Taylor and aims to combine synthetic biology and detection technology into an orally administered pill and urine-based test.The pill will contain engineered sensors designed to detect cancer-related conditions such as acidity and low oxygen, then release signals that indicate tumor presence and location, Ginkgo said Monday in a statement.Ginkgo plans to support the program with its cell and enzyme engineering capabilities.Other participants include researchers from the University of Pittsburgh, the University of Massachusetts Amherst, and KU Leuven, and corporate partners such as Velentium Medical and Platypus Bio.Ginkgo shares rose 8% in recent Monday trading.Price: 8.75, Change: +0.65, Percent Change: +7.96","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}